THE US Food and Drug
Administration has approved
Synribo (omacetaxine
mepesuccinate) for the treatment
of adults with chronic myelogenous
leukaemia (CML) which is a blood
and bone marrow disease.
Synribo works by blocking
certaion proteins which promote
the development of cancerous
cells, and is injected
subcutaneously twice daily for 14
consecutive days over a four week
cycle until white blood cells
normalise in the patient.
A subsequent treatment round
involves twice daily injections for 7
days out of 28 as long as patients
continue to benefit from therapy.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Oct 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Oct 12
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
THE University of South Australia has released a new study to help healthcare workers better support women with persistent pelvic pain, including symptoms that are suggestive of gynaecological, lower urinary tract, bowel, sexual, and pelvic floor dysfunction.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.